Allergic bronchopulmonary aspergillosis in a lung transplant recipient treated with mepolizumab.

Allergic bronchopulmonary aspergillosis (ABPA) is a complex hypersensitivity reaction to Aspergillus spp. ABPA diagnosis may be challenging due to its non-specific presentation. Standard ABPA treatment consists of systemic corticosteroids and antifungal agents. Mepolizumab, a monoclonal antibody against interleukin-5 seems to be a promising treatment for ABPA. Data about ABPA following lung transplantation (LuTx) are scarce. LuTx recipients are at higher risk for adverse effects of ABPA treatment compared to the general population. Here we present a case of a LuTx recipient who was successfully treated with mepolizumab for ABPA following LuTx. Prolonged administration of high dose prednisone was thus avoided. To our knowledge, this is the first case describing mepolizumab administration following LuTx. Mepolizumab seems particularly attractive as a corticosteroid-sparing agent or as an alternative option to antifungal treatments, because of its excellent safety profile and low risk of drug interactions.

Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.

BACKGROUND: Lung function impairment persists in some patients for months after acute coronavirus disease 2019 (COVID-19). Long-term lung function, radiological features, and their association remain to be clarified. OBJECTIVES: We aimed to prospectively investigate lung function and radiological abnormalities over 12 months after severe and non-severe COVID-19. METHODS: 584 patients were included in the Swiss COVID-19 lung study. We assessed lung function at 3, 6, and 12 months after acute COVID-19 and compared chest computed tomography (CT) imaging to lung functional abnormalities. RESULTS: At 12 months, diffusion capacity for carbon monoxide (DLCOcorr) was lower after severe COVID-19 compared to non-severe COVID-19 (74.9% vs. 85.2% predicted, p < 0.001). Similarly, minimal oxygen saturation on 6-min walk test and total lung capacity were lower after severe COVID-19 (89.6% vs. 92.2%, p = 0.004, respectively, 88.2% vs. 95.1% predicted, p = 0.011). The difference for forced vital capacity (91.6% vs. 96.3% predicted, p = 0.082) was not statistically significant. Between 3 and 12 months, lung function improved in both groups and differences in DLCO between non-severe and severe COVID-19 patients decreased. In patients with chest CT scans at 12 months, we observed a correlation between radiological abnormalities and reduced lung function. While the overall extent of radiological abnormalities diminished over time, the frequency of mosaic attenuation and curvilinear patterns increased. CONCLUSIONS: In this prospective cohort study, patients who had severe COVID-19 had diminished lung function over the first year compared to those after non-severe COVID-19, albeit with a greater extent of recovery in the severe disease group.

[Pulmonary tularemia : a diagnosis not to be missed]. / Tularémie pulmonaire : un diagnostic à ne pas manquer.

Tularemia (caused by the facultative intracellular Gram-negative bacillus Francisella tularensis) is an endemic zoonotic disease in Europe, which exhibits different clinical patterns. Following the glandular form, pneumonia is the second most frequent manifestation in Switzerland. Pulmonary tularemia often has a subacute course and fails to respond to beta-lactam antibiotics. It can also mimic tuberculosis, because of the presence of systemic symptoms, such as fever, sweats and weight loss. History of animal exposure is not always reported. Clinicians should be aware of pulmonary tularemia. They should be able to diagnose it with appropriate tools (PCR, serology) and initiate appropriate therapy (fluoroquinolones, tetracyclines or aminoglycosides).

La tularémie (causée par le bacille Gram négatif intracellulaire facultatif Francisella tularensis) est une zoonose endémique en Europe qui peut se présenter sous divers syndromes cliniques. Après la forme glandulaire, la pneumonie est la deuxième manifestation la plus courante en Suisse. La tularémie pulmonaire se caractérise par une évolution souvent subaiguë qui ne répond pas aux antibiotiques de type bêtalactamines. Elle peut aussi être confondue avec une tuberculose en raison des symptômes systémiques associés (fièvre, sudations, perte pondérale). L'exposition animale n'est pas toujours documentée. Il est important pour le clinicien de savoir reconnaître cette forme de pneumonie atypique, la diagnostiquer à l'aide des bons outils (PCR ou sérologie) et la traiter de manière appropriée (fluoroquinolones, tétracyclines ou aminoglycosides).

Endobronchial coil spring fiducial markers for CyberKnife® stereotactic body radiation therapy.

BACKGROUND AND OBJECTIVE: SBRT is an alternative treatment for early-stage inoperable lung cancer. Metallic FM allow to increase tumour tracking precision by CyberKnife®. Currently used techniques for FM placement have many limitations; transthoracic insertion has a high risk for pneumothorax, endovascular insertion requires expertise and dedicated angiography infrastructure and endobronchial linear-gold FM dislocate frequently. This is the first study to assess the safety and efficacy of cs-FM endobronchial insertion under fluoroscopy with or without R-EBUS assessment. METHODS: We retrospectively evaluated all consecutive patients undergoing endobronchial cs-FM placement for at least one PPL <25 mm between 10.2015 and 12.2019. TBB of the PPL were performed in case of a typical R-EBUS signal. PPL tracking accuracy by CyberKnife, complications, cs-FM migration rate and procedure duration were analysed. RESULTS: A total of 52 patients were treated during 55 procedures and 207 cs-FM were placed in 70 PPL. Tracking was successful for 65 of 70 (93%) PPL. R-EBUS was performed for 33 (47%) PPL and TBB for 9 (13%) PPL. Bronchospasm occurred once and any other complications were observed. Migration of cs-FM occurred in 16 of 207 (8%) cs-FM. Migration was more frequent when the target was in a previously irradiated area (P = 0.022). The median bronchoscopy duration was 31.5 min (n = 48 procedures). CONCLUSION: Bronchoscopic cs-FM placement is a rapid and safe procedure. It is associated with a low migration rate and allows precise SBRT delivery. Previous irradiation of the PPL was associated with a higher migration rate.

[Clinical approach to enlarged mediastinal and hilar lymph nodes other than the oncological causes]. / Adénomégalies médiastinohilaires - Approche clinique chez l'adulte immunocompétent hors contexte oncologique.

Widespread use of CT-scans leads to increased discovery of mediastinal and hilar lymph node enlargement, a frequent motive for consulting a pulmonologist. The persistence or progression of such lymphadenopathies outside of an oncological context is most often associated with an infectious process or inflammatory disorders. The history will also point to possible occupational or environmental exposure. The radiological characteristics specific to lymphadenopathies and any associated parenchymal lung damage will most often orient the diagnosis. Endobronchial ultrasound-guided techniques allow targeted and real-time sampling of the mediastinum and hilar lymph nodes, representing the first-line investigation before more invasive surgical procedures.

La découverte d'adénomégalies médiastinohilaires (AMH) est un motif fréquent de consultation en pneumologie. Utilisés à grande échelle, les CT-scans thoraciques en sont les principaux révélateurs. La persistance ou la progression d'AMH en dehors d'un contexte oncologique est le plus souvent d'origine infectieuse ou associée à un processus inflammatoire. L'anamnèse nous orientera vers une possible exposition à des facteurs environnementaux y compris en milieu professionnel. La plupart du temps, les caractéristiques radiologiques propres aux AMH ainsi qu'une éventuelle atteinte parenchymateuse pulmonaire associée pourront orienter le diagnostic. L'échoendoscopie bronchique permettant un échantillonnage ganglionnaire médiastinohilaire ciblé est l'examen de première intention avant des abords diagnostiques plus invasifs.

[Covid-19 respiratory sequelae : Screening and management]. / Séquelles respiratoires liées au Covid-19 : dépistage et prise en charge.

Infection with SARS-CoV-2 can affect multiple organ systems with variable severity and is known to frequently have a major impact on the respiratory system. Symptoms may persist for several months after infection, and are associated with a reduction of lung function, diminished exercise capacity and anomalies on chest CT. Guidelines on the post-acute care of patients with SARS-CoV-2 are now available. Pulmonary rehabilitation plays a central role in the recovery of exercise capacity, notably in severe cases. The role of specific therapies, such as corticosteroids, anti-fibrotics and lung transplantation remains uncertain and needs to be evaluated on a case-by-case basis.

L'infection à SARS-CoV-2 conduit à une atteinte multisystémique de gravité variable, fréquemment avec un impact majeur sur le système respiratoire. Les symptômes peuvent persister plusieurs mois après l'infection initiale. Ils sont parfois associés à une diminution des fonctions pulmonaires et de la capacité à l'effort, ainsi qu'à des anomalies au CT-scan thoracique. Il existe actuellement des recommandations de suivi et de prise en charge des patients atteints par le Covid-19 pour la phase postaiguë. La réhabilitation pulmonaire joue un rôle central dans la récupération de la capacité d'effort, surtout dans les formes sévères. La place des traitements spécifiques des atteintes pulmonaires, notamment les corticostéroïdes, les antifibrotiques et la transplantation, reste encore incertaine et doit être considérée au cas par cas.

Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.

Immune checkpoint inhibitors (ICIs) have been shown to improve overall and progression-free survival in various cancers but have been associated with various immune-related adverse events (IRAEs), including interstitial lung disease, especially organizing pneumonia. We report 2 cases of isolated severe airway disease attributable to ICIs, a rarely reported pattern of lung toxicity. The first patient received nivolumab with or without ipilimumab in a randomized double-blind trial for locoregional metastatic melanoma. The second patient was treated with nivolumab for lung adenocarcinoma. An IRAE was suspected in both cases due to a temporal relationship between ICI initiation and symptom onset. ICIs were stopped, and high-dose prednisone, inhaled corticosteroids, and bronchodilators were administered, allowing a rapid clinical and functional improvement in Patient 1. In Patient 2, despite prolonged high-dose prednisone, only a stabilization of forced expiratory volume in 1 s could be achieved, and the disease course was complicated by respiratory infections resulting in further loss of lung function. The patient died 1 year later due to progression of metastatic disease. These 2 cases suggest that pulmonary IRAEs secondary to ICIs may present as isolated bronchitis or bronchiolitis, with variable outcomes following ICI withdrawal and systemic corticosteroids.

[New developments in systemic sclerosis-associated interstitial lung disease]. / Pneumopathie interstitielle associée à la sclérodermie systémique†: nouveaux développements.

Interstitial lung disease is a frequent complication of systemic sclerosis and has now become the leading cause of death in this disorder. It mainly occurs during the first five years after the diagnosis of systemic sclerosis. Various risk factors are associated with the occurrence of interstitial lung disease, including the presence of anti-topoisomerase I antibodies (Scl-70) and the diffuse cutaneous form of systemic sclerosis. The most common radio-pathological presentation is nonspecific interstitial pneumonia, followed by usual interstitial pneumonia. The classical immunosuppressive treatment of systemic sclerosis-associated interstitial lung disease is evolving, as recent studies suggest a beneficial effect of biological agents such as rituximab and tocilizumab, and antifibrotic drugs such as nintedanib.

La pneumopathie interstitielle est une complication fréquente de la sclérodermie, dont elle est devenue ces dernières années la première cause de mortalité. Elle survient principalement durant les cinq premières années suivant le diagnostic de sclérodermie. Divers facteurs de risque sont associés à sa survenue, dont la présence d'anticorps anti-topoisomérase I (Scl-70) et la forme cutanée diffuse de sclérodermie. La présentation radio-pathologique la plus fréquente est la pneumopathie interstitielle non spécifique, suivie de la pneumopathie interstitielle commune. Le traitement immunosuppresseur classique de la pneumopathie interstitielle associée à la sclérodermie est en évolution, des études récentes suggérant l'efficacité de traitements biologiques comme le rituximab et le tocilizumab, et de médicaments antifibrotiques comme le nintédanib.

[Lung cancer screening in Switzerland†: Who†? How†? When†?] / Dépistage du cancer pulmonaire en Suisse†: Qui†? Comment†? Quand†?

Professional societies encourage the establishment of coordinated national screening programs for lung cancer by «â€…low-dose ¼ chest CT scans. The interdisciplinary Swiss Lung Cancer Screening Implementation Group (CH-LSIG) is exploring the feasibility of such a project. However, several questions still remain unanswered, namely the -financing of such a program, the ideal «â€…number-needed to screen ¼, the definition and follow-up of «â€…positive cases ¼, as well as the role of smoking cessation measures. The key points to discuss in the future with patients requesting screening are based on the «â€…shared -decision-making ¼ approach. Pilot projects guided by the CH-LSIG could help to identify the optimal strategy for establishing a national screening program based on the best available scientific evidence.

Les sociétés savantes encouragent le développement de programmes nationaux de dépistage du cancer pulmonaire par CT-scan thoracique low-dose. En Suisse, le groupe de travail ­interdisciplinaire Swiss Lung Cancer Screening Implementation Group (CH-LSIG) s'emploie à la mise en œuvre d'un tel projet. Néanmoins, de nombreuses questions demeurent encore ouvertes, portant sur le financement d'un tel programme, le Number ­Needed to Screen idéal, la définition des «â€…cas positifs ¼ et l'intégration optimale des mesures de sevrage tabagique. Le concept de décision médicale partagée servira de modèle pour répondre aux futurs patients demandeurs d'un examen de dépistage. Des projets pilotes guidés par le CH-LSIG pourraient permettre d'identifier la stratégie la plus performante afin d'implémenter un programme fondé sur les preuves.

[Lung cancer screening: what can we tell our patients while we await a screening program†?] / Dépistage du cancer du poumon†: que dire à nos patient·e·s en attendant un programme organisé†?

The NLST study in the United States showed, in 2011, that low-dose lung CT scans can reduce lung cancer mortality but was limited in its routine recommendation by 96% of false positive screening results. The European NELSON trial, published in 2020, confirmed a 24% decrease in lung cancer mortality and, by using lung nodule volume and volume doubling time, decreased false positive results to 56% of positive tests. The implementation of screening programs is now expected in Europe, including Switzerland. In anticipation, we have developed a decision aid to present patients with the benefits (decreased lung cancer mortality), risks (false positives and indeterminate results), and uncertainties (incidental findings) of lung cancer screening.

L'étude clinique américaine National Lung Screening Trial a démontré en 2011 que le dépistage du cancer du poumon par CT-scan thoracique à faible dose (low-dose) pouvait en diminuer la mortalité, mais était limité dans son applicabilité par une proportion rédhibitoire de 96 % de faux positifs. L'étude clinique européenne Nederlands-Leuven Screening Onderzoek, publiée en 2020, confirme une diminution de la mortalité du cancer du poumon de 24 % et, en se basant sur le temps de doublement du volume des nodules pulmonaires, a pu réduire la prévalence de faux positifs à 56 %. Des programmes de dépistage se préparent dans plusieurs pays européens, y compris la Suisse. Dans ce contexte, nous avons développé une aide à la décision qui reprend les bénéfices (diminution de la mortalité), les risques (faux positifs et résultats indéterminés) et incertitudes (découvertes fortuites) du dépistage du cancer du poumon.

Diagnosis and treatment of invasive fungal infections: looking ahead.

Improved standards of care depend on the development of new laboratory diagnostic and imaging procedures and the development of new antifungal compounds. Immunochromatography technologies have led to the development of lateral flow devices for the diagnosis of cryptococcal meningitis and invasive aspergillosis (IA). Similar devices are being developed for the detection of histoplasmosis that meet the requirements for speed (∼15 min assay time) and ease of use for point-of-care diagnostics. The evolution of molecular tools for the detection of fungal pathogens has been slow but the introduction of new nucleic acid amplification techniques appears to be helpful, for example T2Candida. An Aspergillus proximity ligation assay has been developed for a rapid near-patient bedside diagnosis of IA. CT remains the cornerstone for radiological diagnosis of invasive pulmonary fungal infections. MRI of the lungs may be performed to avoid radiation exposure. MRI with T2-weighted turbo-spin-echo sequences exhibits sensitivity and specificity approaching that of CT for the diagnosis of invasive pulmonary aspergillosis. The final part of this review looks at new approaches to drug discovery that have yielded new classes with novel mechanisms of action. There are currently two new classes of antifungal drugs in Phase 2 study for systemic invasive fungal disease and one in Phase 1. These new antifungal drugs show promise in meeting unmet needs with oral and intravenous formulations available and some with decreased potential for drug-drug interactions. Novel mechanisms of action mean these agents are not susceptible to the common resistance mechanisms seen in Candida or Aspergillus. Modification of existing antifungal susceptibility testing techniques may be required to incorporate these new compounds.

A black-blood ultra-short echo time (UTE) sequence for 3D isotropic resolution imaging of the lungs.

PURPOSE: Ultra-short echo time MRI is a promising alternative to chest CT for cystic fibrosis patients. Black-blood imaging in particular could help discern small-sized anomalies, such as mucoid plugging, which may otherwise be confused with neighboring blood vessels, particularly when contrast agent is not used. We, therefore, implemented and tested an ultra-short echo time sequence with black-blood preparation. Additionally, this sequence may also be used to generate bright-blood angiograms. METHODS: Using this sequence, data was acquired during free breathing in 10 healthy volunteers to obtain respiratory-motion-resolved 3D volumes covering the entire thorax with an isotropic resolution of (1 mm)3 . The magnitude of signal suppression relative to a bright-blood reference acquisition was quantified and compared with that obtained with a turbo-spin echo (TSE) acquisition. Bright-blood angiograms were also generated by subtraction. Finally, an initial feasibility assessment was performed in 2 cystic fibrosis patients, and images were visually compared with contrast-enhanced images and with CT data. RESULTS: Black-blood preparation significantly decreased the average normalized signal intensity in the vessel lumen (-66%; P < 0.001). Similarly, blood signal was significantly lowered (-60%; P = 0.001) compared with the TSE acquisition. In patients, mucoid plugging could be emphasized in the black-blood datasets. An intercostal artery could also be visualized in the subtraction angiograms. CONCLUSION: Black-blood free-breathing ultra-short echo time imaging was successfully implemented and motion-resolved full volumetric coverage of the lungs with high spatial resolution was achieved, while obtaining an angiogram without contrast agent injection. Encouraging initial results in patients prompt further investigations in a larger cohort.

Ultrashort echo time imaging of the lungs under high-frequency noninvasive ventilation: A new approach to lung imaging.

BACKGROUND: Although ultrashort echo time (UTE) sequences allow excellent assessment of lung parenchyma, image quality remains lower than that of computed tomography (CT). PURPOSE: To investigate a high-frequency noninvasive ventilation (HF-NIV) technique allowing a stabilized inspiration and to compare image quality with current dedicated MR sequences. STUDY TYPE: Prospective. POPULATION: Ten healthy volunteers. FIELD STRENGTH/SEQUENCE: 3D radial UTE sequence at 1.5T. ASSESSMENT: UTE-HF-NIV sequence was compared with UTE-free-breathing (UTE-FB), reconstructed at end expiration (UTE-Exp) and average (UTE-Avg), and breath-hold VIBE sequences. The distance from lung apex to the dome of the right hemidiaphragm was measured. Visual assessment of the visibility and sharpness of normal anatomical structures was carried out. Dedicated software also quantitatively evaluated vessel-lung and right lung-liver interface sharpness. Apparent signal ratio (Sr) and contrast ratios (Cr) were quantitatively evaluated. STATISTICAL TESTS: Wilcoxon signed rank test for visual scores, paired t-test for continuous variables, significance at P < 0.05. RESULTS: The distance between apex and the right hemidiaphragmatic dome was significantly larger (P < 0.001) with UTE-HF-NIV compared with UTE-FB and VIBE acquisitions. Vessel and airway visibility had identical median visual scores with all UTE methods. Median visual scores for sharpness of vessels and airways were significantly higher (P < 0.001) with HF-NIV (vessels = 3; airways = 2) than in UTE-FB (vessels = 2; airways = 1) and VIBE (vessels = 1; airways = 1). Software-based vessel sharpness evaluation resulted in larger values in 8/10 volunteers with UTE-HF-NIV (67.3 ± 9.8) compared with UTE-Avg (62.3 ± 12.6) but the average difference was not significant (P = 0.28). The sharpness of the lung-liver interface was significantly higher (P < 0.001) with HF-NIV (17.3 ± 5.3) compared with UTE-Avg (14.1 ± 3.9). Significantly higher values (P < 0.01) of Sr and Cr were observed with UTE-HF-NIV compared with UTE-FB and VIBE. DATA CONCLUSION: HF-NIV allowing acquisition at full inspiration significantly improves image quality for lung imaging. This could offer the option to alternate some follow-up CT studies by using this technique. LEVEL OF EVIDENCE: 2 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:1789-1797.

Hepatosplenomegaly, pneumopathy, bone changes and fronto-temporal dementia: Niemann-Pick type B and SQSTM1-associated Paget's disease in the same individual.

Data from exome sequencing show that a proportion of individuals in whom a genetic disorder is suspected turn out to have not one, but two to four distinct ones. This may require an evolution in our diagnostic attitude towards individuals with complex disorders. We report a patient with splenomegaly, pneumopathy, bone changes and fronto-temporal dementia (FTD). "Sea-blue histiocytes" in his bone marrow pointed to a lysosomal storage disease. Homozygosity for a pathogenic mutation in the SMPD1 gene confirmed Niemann-Pick disease type B (NPD-B). Mild cognitive impairment and abnormal brain FDG PET were consistent with FTD. We initially tried to fit the skeletal and neurologic phenotype into the NPD-B diagnosis. However, additional studies revealed a pathogenic mutation in the SQSTM1 gene. Thus, our patient had two distinct diseases; NPD-B, and Paget's disease of bone with FTD. The subsequent finding of a mutation in SQSTM1 gene ended our struggle to explain the combination of findings by a singular "unifying" diagnosis and allowed us to make specific therapeutic decisions. SQSTM1 mutations have been reported in association with FTD, possibly because of defective autophagy. Bisphosphonates may be beneficial for PDB, but since they are known to inhibit acid sphingomyelinase activity, we refrained from using them in this patient. While the principle of looking for unifying diagnosis remains valid, physicians should consider the possibility of co-existing multiple diagnoses when clinical features are difficult to explain by a single one. Accurate diagnostic work-up can guide genetic counseling but also lead to better medical management.

[Analysis of chest x-rays, a systematic to remember]. / Analyse de la radiographie thoracique, une systématique à rappeler.

The interpretation of chest x-rays, which is part of a comprehensive medical management, requires a specific mastery, this despite the promising performance of artificial intelligence software. Alternatives to this imaging modality exist, particularly ultra-low dose CT (CT-ULD) and thoracic ultrasound (US) in some indications, but they are not a substitute for chest x-rays in clinical routine. Among the rules to be followed, a systematic reading technique is required, in order to reduce the risk of error. In addition, the observational and interpretive capabilities necessary for this task must be exercised, referring to the normal radiographic aspect. The objective of this article is to demonstrate the interpretation of pathological chest x-rays using clinical cases.

L'interprétation des radiographies thoraciques, qui s'intègre dans une prise en charge médicale globale, requiert une maîtrise spécifique, et ce malgré les performances prometteuses des logiciels d'intelligence artificielle. Des alternatives à cette modalité d'imagerie existent, en particulier le CT ultra-faible (low)-dose (CT-ULD) et l'ultrason (US) thoracique dans certaines indications, mais elles ne s'y substituent pas en routine clinique. Parmi les règles à respecter, une technique de lecture systématique est requise afin de réduire le risque d'erreur. De plus, les capacités d'observation et d'interprétation nécessaires à cette tâche doivent être exercées, et ce en référence à l'aspect radiographique normal. Cet article a pour objectif de démontrer l'interprétation de radiographies thoraciques pathologiques à l'aide de cas cliniques.

[Computer instruments for the management of isolated pulmonary nodule. Detectability and prediction of malignancy]. / Outils informatiques pour la prise en charge du nodule pulmonaire isolé - Détectabilité et prédiction de malignité.

Lung cancer remains the most common cause of cancer deaths in the world, but its mortality can be significantly reduced by diagnosis and early detection. Computerized resources were developed to assist radiologists in their management of the large volume of thoracic images to be analyzed. Their objective is the detection of pulmonary nodules with high sensitivity and a low rate of false-positives and the ability to differentiate benign and malignant nodules. The volume of a pulmonary nodule and its volume doubling time are essential to nodule management. Computer aided detection or diagnosis (CAD) software are not currently used in clinically settings on a routine basis . Significant advances are expected due to the implementation of the artificial intelligence systems who will probably be integrated into the multidisciplinary management of any pulmonary nodule.

Le cancer du poumon reste la principale cause de décès par cancer dans le monde. Sa mortalité peut être significativement réduite par un diagnostic et un dépistage précoce. Des outils informatiques ont été développés afin d'aider les radiologues à gérer la quantité d'images thoraciques à analyser. Ils ont pour objectif la détection des nodules pulmonaires avec une haute sensibilité et un taux faible de faux positifs, mais aussi la différenciation des nodules bénins et malins. Le volume d'un nodule pulmonaire et le temps de doublement déterminent la suite de la prise en charge de ce nodule. Ces deux paramètres sont inclus dans la plupart des recommandations actuelles. Les logiciels de détection assistés par ordinateur (CAD) ne sont pas utilisés en routine clinique actuellement. Des avancées dans ce domaine sont attendues en utilisant l'intelligence artificielle, notamment dans le cadre de la prise de décision multidisciplinaire.

A double echo ultra short echo time (UTE) acquisition for respiratory motion-suppressed high resolution imaging of the lung.

PURPOSE: Magnetic resonance imaging is a promising alternative to computed tomography for lung imaging. However, organ motion and poor signal-to-noise ratio, arising from short T2*, impair image quality. To alleviate these issues, a new retrospective gating method was implemented and tested with an ultra-short echo time sequence. METHODS: A 3D double-echo ultra-short echo time sequence was used to acquire data during free breathing in ten healthy adult subjects. A self-gating method was used to reconstruct respiratory motion suppressed expiratory and inspiratory images. These images were objectively compared to uncorrected data sets using quantitative end-points (pulmonary vessel sharpness, lung-liver interface definition, signal-to-noise ratio). The method was preliminarily tested in two cystic fibrosis patients who underwent computed tomography. RESULTS: Vessel sharpness in expiratory ultra-short echo time data sets with second echo motion detection was significantly higher (13% relative increase) than in uncorrected images while the opposite was observed in inspiratory images. The method was successfully applied in patients and some findings (e.g., hypointense areas) were similar to those from computed tomography. CONCLUSION: Free breathing ultra-short echo time was successfully implemented, allowing flexible image reconstruction of two different respiratory states. Objective improvements in image quality were obtained with the new method and initial feasibility in a clinical setting was demonstrated. Magn Reson Med 79:2297-2305, 2018. © 2017 International Society for Magnetic Resonance in Medicine.

A plea for thoracoscopic resection of solitary pulmonary nodule in cancer patients.

BACKGROUND: Solitary pulmonary nodules (SPN) are frequently detected in cancer patients. These lesions are often considered as pulmonary metastases and increasingly treated by non-surgical techniques without histological confirmation. The aim of this study is to determine the histological nature of SPN resected by thoracoscopy and to identify risk factors of malignancy. METHODS: Single-institution retrospective analysis of all consecutive patients with previously known malignancies who underwent thoracoscopic resection of SPN with unknown diagnosis between 2001 and 2014. RESULTS: One hundred and forty cancer patients underwent thoracoscopic resection of a SPN. The resected SPN was benign in 34 patients (24.3%) and malignant in 106 patients. The latter were metastasis in 70 patients (50%) and a primary lung cancer in 36 patients (25.7%). Upon univariate analysis, malignancy was significantly associated with age >60 years, disease-free interval ≥24 months, SPN size >8 mm, upper lobe localization and SUVmax > 2.5 on PET-CT. Upon multivariate analysis, upper lobe localization and SUVmax > 2.5 were associated with malignancy. Smoking was significantly associated with SPN containing primary lung cancer. CONCLUSION: In this series, only 50% of SPN in patients with known malignant disease were pulmonary metastases and 25% had a newly diagnosed NSCLC. Smoking was associated with primary lung cancer but no other predictor was found to allow the distinction between pulmonary metastasis and lung cancer. These results endorse the need of histological confirmation of SPN in patients with previous malignancies to avoid diagnostic uncertainty and suboptimal treatments.

Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.

Chronic pulmonary aspergillosis (CPA) is an uncommon and problematic pulmonary disease, complicating many other respiratory disorders, thought to affect ~240 000 people in Europe. The most common form of CPA is chronic cavitary pulmonary aspergillosis (CCPA), which untreated may progress to chronic fibrosing pulmonary aspergillosis. Less common manifestations include: Aspergillus nodule and single aspergilloma. All these entities are found in non-immunocompromised patients with prior or current lung disease. Subacute invasive pulmonary aspergillosis (formerly called chronic necrotising pulmonary aspergillosis) is a more rapidly progressive infection (<3 months) usually found in moderately immunocompromised patients, which should be managed as invasive aspergillosis. Few clinical guidelines have been previously proposed for either diagnosis or management of CPA. A group of experts convened to develop clinical, radiological and microbiological guidelines. The diagnosis of CPA requires a combination of characteristics: one or more cavities with or without a fungal ball present or nodules on thoracic imaging, direct evidence of Aspergillus infection (microscopy or culture from biopsy) or an immunological response to Aspergillus spp. and exclusion of alternative diagnoses, all present for at least 3 months. Aspergillus antibody (precipitins) is elevated in over 90% of patients. Surgical excision of simple aspergilloma is recommended, if technically possible, and preferably via video-assisted thoracic surgery technique. Long-term oral antifungal therapy is recommended for CCPA to improve overall health status and respiratory symptoms, arrest haemoptysis and prevent progression. Careful monitoring of azole serum concentrations, drug interactions and possible toxicities is recommended. Haemoptysis may be controlled with tranexamic acid and bronchial artery embolisation, rarely surgical resection, and may be a sign of therapeutic failure and/or antifungal resistance. Patients with single Aspergillus nodules only need antifungal therapy if not fully resected, but if multiple they may benefit from antifungal treatment, and require careful follow-up.